Search by Abstract Number Results

Abstract Number: 0908 • ACR Convergence 2024
Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci
Nina Oparina¹, Sarah Reid², Ahmed Sayadi³, Maija-Leena Eloranta⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Solbritt Rantapaa-Dahlqvist⁸, Anders Bengtsson⁷, Anna Rudin⁹, Øyvind Molberg¹⁰, Christopher Sjowall¹¹, Lars Rönnblom⁴ and Dag Leonard⁴, ¹UU, Uppsala, Sweden, ²Uppsala University, Medical Sciences, Uppsala, Sweden, ³Uppsala, Uppsala, Sweden, ⁴Uppsala University, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Umeå University, Umeå, Sweden, ⁹Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹⁰Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹¹Linköping University, Linköping, Sweden
Background/Purpose: Heritability of SLE is high and more than 200 genetically associated SLE risk loci were identified. Part of them are specific and associate with…
Abstract Number: 0908 • ACR Convergence 2023
Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function
Tammy Nowling, bethany wolf, Calvin Blaschke, Richard Drake, Sandra Sanchez, Mariia Stefanenko, Mykhailo Fedoriuk, Oleg Palygin, Hongxia Bai and Jessalyn Rodgers, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE primarily afflicts women and many SLE patients develop nephritis, a serious complication of lupus. Identification of biomarkers and the pathogenic mechanisms underlying LN…
Abstract Number: 0908 • ACR Convergence 2022
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
Arkady Manning-Bennett¹, Ashley Hopkins², Michael Sorich², Susanna Proudman³, David Foster¹, Ahmad Abuhelwa² and Michael Wiese¹, ¹University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…
Abstract Number: 0908 • ACR Convergence 2021
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study
Uta Kiltz¹, Xenofon Baraliakos¹, Jan Brandt-Jrgens², Ulf Wagner³, Sebastian Lieb⁴, Christian Sieder⁵, Christian Mann⁵ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Universitätsklinikum Leipzig, Leipzig, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side…
Abstract Number: 0908 • ACR Convergence 2020
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Atul Deodhar¹, Philip Mease², Wolf-Henning Boehncke³, John Tesser⁴, Elena Schiopu⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, May Shawi¹⁰, Yusang Jiang¹¹, Shihong Sheng¹¹, Prasheen Agarwal¹¹, Joseph Merola¹², Iain McInnes¹³ and Christopher Ritchlin¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Michigan Medicine, Ann Arbor, MI, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Global Services, LLC, Toronto, ON, Canada, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ¹³Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ¹⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the IL-23p19-subunit, has shown consistent efficacy in psoriasis pts regardless of body weight/body mass index (BMI).1 GUS…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].